- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Strong industry interest in SilvaGard, a breakthrough antimicrobial nanotechnology, has resulted in significant growth for AcryMed, the company that developed and now licenses the technology. Built on years of research in developing silver antimicrobial wound treatments, SilvaGard addresses a still un-met clinical need, preventing the spread of deadly medical device-related infections. By harnessing the advantages of nanotechnology with the broad-spectrum infection-fighting ability of Ionic silver, SilvaGard provides a safe and effective solution to render medical devices impervious to infection causing biofilms.
To accommodate the increased demand for its patented technologies, AcryMed has recently doubled the size of its laboratory facilities and hired new scientific and technical staff. According to AcryMed, the company has received inquiries that span a large number of medical device markets.
"The spread of hospital acquired infections is a significant problem that unnecessarily effect millions of U.S. patients each year and adds more than 28 billion dollars to our nation's healthcare costs," said Jack McMaken, president of AcryMed. "Since a large portion of harmful bacteria is harbored on medical devices such as indwelling catheters and implants, manufacturers are extremely interested in finding ways to curtail the role their products play in spreading infections. SilvaGard represents the first significant breakthrough in this area in quite some time."
SilvaGard prevents the spread of device-related infections by depositing antimicrobial silver nanoparticles onto the surfaces of medical devices and thus providing a protective barrier. Studies have shown that SilvaGard is not only safe for use, but also highly effective against a wide spectrum of infection-causing bacteria including MRSA and other antibiotic-resistant "superbugs."
The initial FDA market clearance of SilvaGard antimicrobial technology was given to I-Flow Corporation for marketing the company's ON-Q® SilverSoaker™ regional anesthesia delivery catheters. In recent findings presented at the Surgical Infection Society (SIS) meeting, I-Flow's ON-Q SilverSoaker antimicrobial catheter demonstrated a significantly lower risk of developing a surgical site infection in an on-going prospective study of patients undergoing colorectal surgery. The preliminary results captured the outcomes of 120 patients, randomized to either treatment with continuous local anesthetic using the antimicrobial treated ON-Q catheter or to the control treatment employing traditional pain relief. At 30-days post surgery, patients who received treatment with the antimicrobial ON-Q device had a significantly lower incidence of site infections at 0%, as compared to the control group at 22.9%. The study is scheduled to be complete by year-end. To learn more about the benefits of the ON-Q, visit www.AskYourSurgeon.com or www.IFLO.com.
Through collaborative development efforts, AcryMed and its medical device company partners expect to announce new product applications, leveraging SilvaGard-technology in the coming months.
cryMed is a pioneering innovator at the forefront of innovations in the fields of infection control and wound healing. The company's SilvaSorb® products for advanced wound care and SilvaGard nanoparticle surface treatment for medical devices are among the breakthrough technologies that have distinguished AcryMed as an industry leader. AcryMed maintains on-site GMP manufacturing and lab facilities at its Portland, Oregon-based headquarters. The company is ISO certified and operates under ISO 13485 and EN 93/42/EEC. For more information on AcryMed, SilvaSorb, SilvaGard or other wound care and infection control technologies developed by AcryMed, visit their web site at http://www.acrymed.com or call 503-624-9830.
For more information, please click here
9560 SW Nimbus Ave.
Beaverton, Oregon 97008
Phone Number: 503.624.9830
Fax Number: 503.639.0846
Copyright © PRWeb™If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Leti Announces Launch of First European Nanomedicine Characterisation Laboratory: Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval July 1st, 2015
High-tech nanofibres could help nutrients in food hit the spot June 17th, 2015